Derivatives of nitrosoureas in treatment of patients with neuroendocrine tumors. Clinical case of successful treatment of patient with disseminated highly differentiated neuroendocrine pancreatic tumor with severe carcinoid syndrome in fourth line of therapy
https://doi.org/10.33667/2078-5631-2020-20-38-41
Abstract
Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Approaches to the second and subsequent lines of treatment have not been developed to date Aranosa is a derivative of nitrosourea. it is close to streptozotocin in terms of its chemical structure, but it has a more favorable toxicity profile. Aranoza is actively studied in well differentiated NET. The drug was effective in the fourth line of treatment of the patient with NET and liver metastases.
About the Authors
S. G. Bagrova
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
G. S. Emelyanova
Moscow State University of Medicine and Dentistry n.a. A. I. Evdokimov
Russian Federation
Russian Federation
Moscow
V. A. Gorbunova
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
A. A. Kolomeytseva
Moscow Research Institute n.a. P. A. Herzen - a Branch of the National Medical Radiological Research Centre
Russian Federation
Russian Federation
Moscow
N. V. Lyubimova
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
А. A. Markovich
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
N. S. Besova
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
Е. I. Kovalenko
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
E. V. Artamonova
Russian National Research Medical University n.a. N.I. Pirogov; Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky
Russian Federation
Russian Federation
Moscow
References
1. . Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26 (18): 3063-72. DOI: 10.1200/JCO.2007.15.4377.
2. Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus); North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug; 39 (6): 784-98. DOI: 10.1097/MPA.0b013e3181ec1380.
3. Broder LE, Carter SK.Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med. 1973 Jul; 79 (1): 108-18.
4. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozo-cin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.N Engl J Med. 1992 Feb 20; 326 (8): 519-23.
5. Moertel CG, Hanley JA, Johnson LA.Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980 Nov20; 303 (21): 1189-94.
6. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984 Nov; 2 (11): 1255-9.
7. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma.Cancer. 1999 Sep 15; 86 (6): 944-8.
8. Eriksson B, Arnberg H, Lindgren PG, Lorelius LE, Magnusson A, Lundqvist G, Skogseid B, Wide L, WilanderE, Oberg K. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med. 1990 Aug; 228 (2): 103-13.
9. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008 Feb; 103 (2): 475-83; quiz 484. Epub 2007 Nov 19. Review.
10. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 1; 22 (23): 4762-71. Erratum in: J Clin Oncol. 2005 Jan 1; 23 (1): 248.
11. Горбунова В. А., Манзюк Л. В., Орел Н. Ф. и др. Араноза - новый отечественный противоопухолевый препарат. Вопросы онкологии. 2001. № 6. С. 672-575.
12. C. А. Полозкова, В. А. Горбунова, В. В. Делекторская, Н. Ф. Орел, Н. Н. Козлов, А. Е. Кузьминов, А. А. Маркович, А. С. Одинцова, Г. С. Емельянова. Факторы прогноза эффективности терапии нейроэндокринных новообразований режимами на основе аранозы. Российский биотерапевтический журнал. 2017. 1, том 16. С. 38-46.
Review
For citations:
Bagrova S.G., Emelyanova G.S., Gorbunova V.A., Kolomeytseva A.A., Lyubimova N.V., Markovich А.A., Besova N.S., Kovalenko Е.I., Artamonova E.V. Derivatives of nitrosoureas in treatment of patients with neuroendocrine tumors. Clinical case of successful treatment of patient with disseminated highly differentiated neuroendocrine pancreatic tumor with severe carcinoid syndrome in fourth line of therapy. Medical alphabet. 2020;(20):38-41. (In Russ.) https://doi.org/10.33667/2078-5631-2020-20-38-41
Views:
428
Email this article 